Neurosense Therapeutics is trading 6.2% up at $4.28, with available sources not establishing a direct cause for the October 6 intraday rise. - On October 2, the company said it plans to appeal Nasdaq’s determination over the $35 million minimum market-value requirement and seek more time to regain compliance. A timely hearing request would stay suspension while the panel considers the appeal. - It also said it had regained compliance with Nasdaq’s minimum bid-price rule. No October 6 company announcement appeared in its investor-relations news feed.